Principal / Senior Principal Scientist, DMPK

Reporting to the Chief Scientific Officer, this role leads DMPK strategy and oversees bioanalytical work across nonclinical and clinical programs, operating as a hands-on scientific leader. We are looking for an accomplished DMPK scientist with experience in PK and PK-PD study design, PK data analysis and interpretation, and translational biomarker strategy. This person will support pharmacology and nonclinical toxicology programs, providing broader context across the nonclinical development portfolio. The ideal candidate brings deep scientific expertise and a hands-on approach and thrives in the fast-paced environment of a clinical-stage biotech where both scientific and strategic contributions are expected. Responsibilities Lead DMPK strategy and oversee bioanalytical work across nonclinical and clinical programs, including PK, biomarker, and translational PD readoutsOversee development, qualification, and validation of nonclinical and clinical bioanalytical assays (GLP/GCP-compliant as required), as well as sample analysis, working with internal and CRO analytical scientistsDesign, execute, and oversee PK and PK-PD studies of tRNAs to evaluate delivery technologies (LNP and others), biodistribution, and biomarker effectsLead PK and PK-PD data analysis and interpretation across mouse, rat, NHP, and human studies to support dose selectionManage and qualify CRO and external lab partners across bioanalytical and PK programsSupport nonclinical toxicology programs in collaboration with internal teams and CROsAnalyze, interpret, and present DMPK and translational biomarker data to internal leadership and external stakeholdersAuthor nonclinical sections of regulatory filings (e.g., IND) and briefing documents; support agency interactions and responsesServe on the Research Leadership Team; represent DMPK and bioanalytical sciences in cross-functional program discussionsManage and develop direct report(s); collaborate with the broader pharmacology team Required Qualifications PhD or equivalent in pharmacokinetics, pharmacology, biochemistry, or related field8+ years of industry experience in DMPK or a closely related functionWorking knowledge of bioanalytical methods (e.g., LC-MS/MS, ligand binding assays, NGS) sufficient to oversee their development, qualification, and validation and the associated sample analysis in nonclinical and clinical contextsDemonstrated CRO oversight - vendor qualification, study monitoring, data reviewExperience designing and overseeing in vivo nonclinical PK and PK-PD studies for novel delivery modalities; LNP experience preferredHands-on experience with PK and PK-PD data analysis (e.g., noncompartmental analysis) and associated software (e.g., Phoenix WinNonlin), applied to the design and interpretation of nonclinical and clinical studiesExperience in translational or clinical biomarker development, including assay strategy and fit-for-purpose qualificationStrong scientific writing skills - regulatory documents (e.g., IND nonclinical sections) and internal study reportsExperience supervising and developing scientists Preferred Qualifications Experience in rare disease or genetic medicineExperience with RNA-based therapiesFamiliarity with LNP platform biology and delivery landscapeFamiliarity with GLP toxicology study design and ICH nonclinical guidelinesExperience operating in a cross-functional leadership role at a clinical-stage biotechExperience with ligand binding assays and multiplex immunoassay platforms (e.g., MSD, Luminex) for cytokine, immunogenicity, and biomarker analysis About Alltrna Alltrna is the first clinical-stage biotech company advancing tRNA medicines to address shared disease-causing mutations across many indications. The company’s initial therapeutic programs are designed to restore full-length protein production in diseases caused by premature termination codons (PTCs), collectively referred to as Stop Codon Disease, which affects approximately 10% of people with a rare genetic disease. Alltrna’s lead program, AP003, is a chemically modified, engineered tRNA oligonucleotide encapsulated in a clinically validated, liver-directed lipid nanoparticle. AP003 is being developed for the arginine-to-TGA (Arg-TGA) PTC in patients with liver Stop Codon Disease, including phenylketonuria, organic acidemias, and urea cycle disorders. Founded in 2018 by Flagship Pioneering, Alltrna has built an integrated platform to design, optimize, and deliver engineered tRNA therapeutics. For more information, visit www.alltrna.com The salary range for this role is $179,000 - $236,000. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. Alltrna currently offers healthcare coverage, annual incentive program, retirement benefits and a broad range of other benefits. Compensation and benefits information is based on Alltrna's good faith estimate as of the date of publication and may be modified in the future. Privacy Notice for Applicants: When you apply for a role at Flagship Pioneering or one of its portfolio companies, we collect and use personal information you provide (such as your name, contact details, work history, and application materials) to evaluate your application, communicate with you, and comply with legal obligations. Your application data is processed through Greenhouse, our applicant tracking system, and may also be reviewed using AI-assisted screening tools. We do not sell your personal information. California residents have rights under the CCPA/CPRA including to know, delete, and opt out of the sharing of their personal information. If you are located in the EU or UK, we process your data under GDPR and you have rights to access, rectify, and erase your data. To exercise your rights or for questions, contact privacy@flagshippioneering.com.